RLMD
RLMD
US75955J4022
Relmada Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
59.100.200 83.891.036
29.6%
Operating Income -59.100.200 -83.891.036
29.6%
Pretax Income -57.385.163 -79.979.354
28.3%
Net Income Common Stockholders -57.385.163 -79.979.354
28.3%
-- --
--
-- --
--
ende